Proxima vs IBM
Side-by-side comparison of AI visibility scores, market position, and capabilities
AI drug discovery for protein-protein interactions; raised $80M seed from DCVC and NVIDIA (Jan 2026); oncology and neurodegeneration focus; opens class of previously undruggable targets
About
Proxima is an AI-driven drug discovery company focused on proteins that control critical biological interactions — specifically targeting protein-protein interactions (PPIs) that have historically been considered undruggable. Founded by researchers with backgrounds in structural biology, machine learning, and medicinal chemistry, Proxima uses AI to design novel therapeutics that can modulate these complex binding interfaces, opening up a vast new class of drug targets for conditions ranging from cancer to neurodegeneration.\n\nThe company's platform integrates protein structure prediction, generative molecular design, and experimental validation in a tightly coupled loop. By leveraging AI models trained on structural and interaction data, Proxima can propose drug candidates targeting previously inaccessible sites on proteins. This approach is particularly relevant for oncology and immunology, where many of the most important biological pathways are mediated by protein complexes that small molecules have struggled to disrupt.\n\nProxima raised an $80M seed round backed by DCVC and NVIDIA in January 2026, one of the largest seed rounds in biotech history. NVIDIA's involvement underscores the computational intensity of the platform and the strategic value of GPU infrastructure partnerships in AI drug discovery. The company is pre-clinical but is building a pipeline of candidates targeting high-value undruggable proteins, with the $80M runway intended to advance multiple programs toward IND filings.
Armonk NY hybrid cloud and enterprise AI (NYSE: IBM) at $62.8B revenue; $6B+ generative AI bookings, record $12.7B free cash flow 2024, DataStax acquisition for watsonx vector database competing with Microsoft Azure for enterprise AI.
About
International Business Machines Corporation (IBM) is an Armonk, New York-based global technology and consulting company — publicly traded on the New York Stock Exchange (NYSE: IBM) as an S&P 500 component — providing hybrid cloud infrastructure, artificial intelligence software, and enterprise IT consulting through approximately 270,300 employees in 170 countries with $62.8 billion in annual revenue. Founded on June 16, 1911, as Computing-Tabulating-Recording Company through a merger orchestrated by financier Charles Ranlett Flint, renamed IBM in 1924 under Thomas Watson Sr., IBM has undergone multiple strategic transformations over its 110+ year history: building the System/360 mainframe platform (1964), launching the IBM PC (1981), selling the PC division to Lenovo (2005, $1.75B), and completing the $34 billion Red Hat acquisition (2019) that repositioned IBM as a hybrid cloud platform company. CEO Arvind Krishna (appointed April 2020) has focused IBM's strategy on three areas: hybrid cloud (powered by Red Hat OpenShift, the enterprise Kubernetes platform), AI (the watsonx platform for enterprise AI model development and deployment), and enterprise consulting. Under Krishna, IBM recorded $12.7 billion in free cash flow in 2024 (a company record), surpassed $6 billion in generative AI bookings since June 2023, and saw the stock price double — trading at all-time highs through 2024-2025. IBM announced the DataStax acquisition in 2025 to deepen watsonx's data layer with AstraDB (vector database for AI applications), DataStax Enterprise (Apache Cassandra), and Langflow (low-code AI agent development).
AI Visibility Head-to-Head
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.